Literature DB >> 11896542

IL-1beta expression in IgM monoclonal gammopathy and its relationship to multiple myeloma.

K A Donovan1, M Q Lacy, M A Gertz, J A Lust.   

Abstract

We have shown that IL-1beta is not detectable in normal plasma cells but is produced by plasma cells from virtually all patients with multiple myeloma (MM). To extend our earlier work, IL-1beta expression was determined in 13 newly diagnosed patients with IgM monoclonal gammopathy. Eleven patients with Waldenstrom's macroglobulinemia (WM) and two patients with IgM MM were investigated for IL-1beta expression by in situ hybridization (ISH). All patients with WM had bone marrow biopsies consistent with the diagnosis, an IgM M-protein in the serum, and subsequently required chemotherapy. Seven of 11 patients with WM had an M-protein >3 g/dl and five patients had bone surveys performed that were negative for osteolytic disease. Two patients were diagnosed with IgM MM because of the presence of significant osteolytic disease on a metastatic bone survey. ISH for kappa, lambda, and IL-1beta expression was performed on bone marrow aspirates from each of the 13 patients. None of the neoplastic cells from the 11 patients with WM showed detectable IL-1beta expression by ISH. However, the neoplastic cells from both patients with IgM MM expressed IL-1beta mRNA at high levels. This aberrant IL-1beta production may explain the presence of bone lesions in the patients with IgM MM.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11896542     DOI: 10.1038/sj.leu.2402374

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  6 in total

1.  IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia.

Authors:  Steven R Schuster; Sundararajan Vincent Rajkumar; Angela Dispenzieri; William Morice; Alvaro Moreno Aspitia; Stephen Ansell; Robert Kyle; Joseph Mikhael
Journal:  Am J Hematol       Date:  2010-11       Impact factor: 10.047

Review 2.  Macrophages in multiple myeloma: emerging concepts and therapeutic implications.

Authors:  Fotis Asimakopoulos; Jaehyup Kim; Ryan A Denu; Chelsea Hope; Jeffrey L Jensen; Samuel J Ollar; Ellen Hebron; Claire Flanagan; Natalie Callander; Peiman Hematti
Journal:  Leuk Lymphoma       Date:  2013-04-11

Review 3.  Iron in multiple myeloma.

Authors:  Kristina VanderWall; Tracy R Daniels-Wells; Manuel Penichet; Alan Lichtenstein
Journal:  Crit Rev Oncog       Date:  2013

4.  Assessment of proliferating cell nuclear antigen and its relationship with proinflammatory cytokines and parameters of disease activity in multiple myeloma patients.

Authors:  G Tsirakis; C A Pappa; M Kaparou; V Katsomitrou; A Hatzivasili; T Alegakis; A Xekalou; E N Stathopoulos; M G Alexandrakis
Journal:  Eur J Histochem       Date:  2011-08-27       Impact factor: 3.188

Review 5.  The emerging roles of inflammasome-dependent cytokines in cancer development.

Authors:  Hanne Van Gorp; Mohamed Lamkanfi
Journal:  EMBO Rep       Date:  2019-05-17       Impact factor: 8.807

6.  pIL6-TRAIL-engineered umbilical cord mesenchymal/stromal stem cells are highly cytotoxic for myeloma cells both in vitro and in vivo.

Authors:  Paola Cafforio; Luigi Viggiano; Francesco Mannavola; Eleonora Pellè; Concetta Caporusso; Eugenio Maiorano; Claudia Felici; Francesco Silvestris
Journal:  Stem Cell Res Ther       Date:  2017-09-29       Impact factor: 6.832

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.